A judge has rejected OxyContin maker Purdue Pharma’s bankruptcy settlement of thousands of lawsuits over the opioid epidemic because of a provision that would protect members of the Sackler family from facing litigation of their own.
in cash and charitable assets as part of an overall deal that could be worth $10 billion, including the value of the new drugs, if they’re brought to market.
Most state and local governments, Native American tribes, individual opioid victims and others who voted said the plan worked out in the bankruptcy court should be accepted. The main issue on the appeal was the lawfulness of the measures that would extend legal protections to family members.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Judge Throws Out Purdue Pharma’s Deal to Shield Sacklers From Opioid LawsuitsA federal judge overturned a roughly $4.5 billion settlement between OxyContin maker Purdue and members of the Sackler family who own the drugmaker, a surprising decision that raises questions about the future of the company and its owners
Weiterlesen »
Judge rejects Purdue Pharma’s sweeping opioid settlement | AP NewsNEW YORK (AP) — A judge has rejected OxyContin maker Purdue Pharma’s bankruptcy settlement of thousands of lawsuits over the opioid epidemic because of a provision that would protect members of the Sackler family from facing litigation of their own.
Weiterlesen »
Judge rejects Purdue Pharma’s sweeping opioid settlement | AP NewsNEW YORK (AP) — A judge has rejected OxyContin maker Purdue Pharma’s bankruptcy settlement of thousands of lawsuits over the opioid epidemic because of a provision that would protect members of the Sackler family from facing litigation of their own.
Weiterlesen »
Judge Throws Out Purdue Pharma’s Deal to Shield Sacklers From Opioid LawsuitsA federal judge overturned a roughly $4.5 billion settlement between OxyContin maker Purdue and members of the Sackler family who own the drugmaker, a surprising decision that raises questions about the future of the company and its owners
Weiterlesen »